1,574 reports of this reaction
1.6% of all Abilify Maintena reports
#10 most reported adverse reaction
SUICIDAL IDEATION is the #10 most commonly reported adverse reaction for Abilify Maintena, manufactured by Otsuka America Pharmaceutical, Inc.. There are 1,574 FDA adverse event reports linking Abilify Maintena to SUICIDAL IDEATION. This represents approximately 1.6% of all 96,636 adverse event reports for this drug.
Patients taking Abilify Maintena who experience suicidal ideation should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
SUICIDAL IDEATION is a less commonly reported adverse event for Abilify Maintena, but still significant enough to appear in the safety profile.
In addition to suicidal ideation, the following adverse reactions have been reported for Abilify Maintena:
The following drugs have also been linked to suicidal ideation in FDA adverse event reports:
SUICIDAL IDEATION has been reported as an adverse event in 1,574 FDA reports for Abilify Maintena. This does not prove causation, but indicates an association observed in post-market surveillance data.
SUICIDAL IDEATION accounts for approximately 1.6% of all adverse event reports for Abilify Maintena, making it a notable side effect.
If you experience suicidal ideation while taking Abilify Maintena, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.